INHIBITING THE RENIN-ANGIOTENSIN SYSTEM TO PREVENT WASTING IN CANCER
Grant number: 1023178 | Funding period: 2012 - 2018
Cancer cachexia is a devastating disease characterised by skeletal muscle wasting and weakness. It impairs patient quality of life and accounts for >20% of cancer-related deaths. My work aims to identify factors contributing to the development of cancer cachexia. This insight will then enable me to test potential strategies to prevent the wasting seen in cancer patients to improve their quality of life and to reduce mortality.
Related publications (4)
Mas Receptor Activation Slows Tumor Growth and Attenuates Muscle Wasting in Cancer
Kate T Murphy, Mohammed I Hossain, Kristy Swiderski, Annabel Chee, Timur Naim, Jennifer Trieu, Vanessa Haynes, Suzannah J Read, David I Stapleton, Sarah M Judge, Jose G Trevino, Andrew R Judge, Gordon S Lynch
Cancer cachexia is a multifactorial syndrome characterized by a progressive loss of skeletal muscle mass associated with significa..
Smad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice
Catherine E Winbanks, Kate T Murphy, Bianca C Bernardo, Hongwei Qian, Yingying Liu, Patricio V Sepulveda, Claudia Beyer, Adam Hagg, Rachel E Thomson, Justin L Chen, Kelly L Walton, Kate L Loveland, Julie R McMullen, Buel D Rodgers, Craig A Harrison, Gordon S Lynch, Paul Gregorevic
Patients with advanced cancer often succumb to complications arising from striated muscle wasting associated with cachexia. Excess..
Elevated expression of activins promotes muscle wasting and cachexia
Justin L Chen, Kelly L Walton, Catherine E Winbanks, Kate T Murphy, Rachel E Thomson, Yogeshwar Makanji, Hongwei Qian, Gordon S Lynch, Craig A Harrison, Paul Gregorevic
In models of cancer cachexia, inhibiting type IIB activin receptors (ActRIIBs) reverse muscle wasting and prolongs survival, even ..